SK70999A3 - Transfecting composition usable in gene therapy combining a recombinant virus incorporating an exogenous nucleic acid, a non-viral and non-plasmid transfecting agent - Google Patents

Transfecting composition usable in gene therapy combining a recombinant virus incorporating an exogenous nucleic acid, a non-viral and non-plasmid transfecting agent Download PDF

Info

Publication number
SK70999A3
SK70999A3 SK709-99A SK70999A SK70999A3 SK 70999 A3 SK70999 A3 SK 70999A3 SK 70999 A SK70999 A SK 70999A SK 70999 A3 SK70999 A3 SK 70999A3
Authority
SK
Slovakia
Prior art keywords
composition
group
nucleic acid
composition according
independently
Prior art date
Application number
SK709-99A
Other languages
English (en)
Slovak (sk)
Inventor
Nathalie Aubailly
Patrick Benoit
Didier Branellec
Roux Aude Le
Abderrahim Mahfoudi
Nathalie Ratet
Original Assignee
Rhone Poulenc Rorer Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Rorer Sa filed Critical Rhone Poulenc Rorer Sa
Publication of SK70999A3 publication Critical patent/SK70999A3/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/10—Vectors comprising a non-peptidic targeting moiety
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/40—Vectors comprising a peptide as targeting moiety, e.g. a synthetic peptide, from undefined source
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
    • C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
    • C12N2810/859—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from immunoglobulins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Plant Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SK709-99A 1996-11-29 1997-11-28 Transfecting composition usable in gene therapy combining a recombinant virus incorporating an exogenous nucleic acid, a non-viral and non-plasmid transfecting agent SK70999A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9614693A FR2756491B1 (fr) 1996-11-29 1996-11-29 Composition transfectante utile en therapie genique associan t a un virus recombinant incorporant un acide nucleique exog ene, un agent de transfection non viral et non plasmidique
PCT/FR1997/002157 WO1998023765A1 (fr) 1996-11-29 1997-11-28 Composition transfectante utile en therapie genique associant a un virus recombinant incorporant un acide nucleique exogene, un agent de transfection non viral et non plasmidique

Publications (1)

Publication Number Publication Date
SK70999A3 true SK70999A3 (en) 2000-03-13

Family

ID=9498192

Family Applications (1)

Application Number Title Priority Date Filing Date
SK709-99A SK70999A3 (en) 1996-11-29 1997-11-28 Transfecting composition usable in gene therapy combining a recombinant virus incorporating an exogenous nucleic acid, a non-viral and non-plasmid transfecting agent

Country Status (13)

Country Link
EP (1) EP0948636A1 (fr)
JP (1) JP2001514485A (fr)
KR (1) KR20000057307A (fr)
AU (1) AU737846B2 (fr)
BR (1) BR9713434A (fr)
CA (1) CA2272637A1 (fr)
CZ (1) CZ188299A3 (fr)
FR (1) FR2756491B1 (fr)
HU (1) HUP9904201A3 (fr)
IL (1) IL130053A0 (fr)
NO (1) NO992577L (fr)
SK (1) SK70999A3 (fr)
WO (1) WO1998023765A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100764890B1 (ko) * 2005-11-14 2007-10-09 한국화학연구원 폴리에틸렌이민과 인지질을 접합하여 제조된 리포솜을이용한 항암주사제 및 이의 제조방법
US9273300B2 (en) 2007-02-07 2016-03-01 Strike Bio, Inc Methods and compositions for modulating sialic acid production and treating hereditary inclusion body myopathy
KR100980395B1 (ko) 2008-06-27 2010-09-07 재단법인서울대학교산학협력재단 비-바이러스성 유전자 전달체용 중합체/유전자 복합체
JP5944622B2 (ja) * 2011-04-08 2016-07-05 株式会社ブリヂストン 遺伝子導入剤組成物
KR102101210B1 (ko) 2012-03-02 2020-04-16 고쿠리츠켄큐카이하츠호진 카가쿠기쥬츠신코키코 기능성 핵산 분자의 구축법, 및 상기 방법에 사용하는 핵산 조합물

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2646161B1 (fr) * 1989-04-17 1991-07-05 Centre Nat Rech Scient Nouvelles lipopolyamines, leur preparation et leur emploi
US5552309A (en) * 1994-09-30 1996-09-03 Indiana University Foundation Use of polyols for improving the introduction of genetic material into cells
FR2727679B1 (fr) * 1994-12-05 1997-01-03 Rhone Poulenc Rorer Sa Nouveaux agents de transfection et leurs applications pharmaceutiques
FR2730637B1 (fr) * 1995-02-17 1997-03-28 Rhone Poulenc Rorer Sa Composition pharmaceutique contenant des acides nucleiques, et ses utilisations
FR2741066B1 (fr) * 1995-11-14 1997-12-12 Rhone Poulenc Rorer Sa Nouveaux agents de transfection et leurs applications pharmaceutiques

Also Published As

Publication number Publication date
HUP9904201A3 (en) 2002-01-28
HUP9904201A1 (hu) 2000-04-28
CZ188299A3 (cs) 1999-09-15
FR2756491A1 (fr) 1998-06-05
EP0948636A1 (fr) 1999-10-13
FR2756491B1 (fr) 1999-01-08
IL130053A0 (en) 2000-02-29
WO1998023765A1 (fr) 1998-06-04
NO992577L (no) 1999-07-28
KR20000057307A (ko) 2000-09-15
NO992577D0 (no) 1999-05-28
JP2001514485A (ja) 2001-09-11
AU7401098A (en) 1998-06-22
CA2272637A1 (fr) 1998-06-04
AU737846B2 (en) 2001-08-30
BR9713434A (pt) 2000-02-01

Similar Documents

Publication Publication Date Title
US5928944A (en) Method of adenoviral-medicated cell transfection
US6172048B1 (en) Composition containing nucleic acids, preparation and uses
JP4275728B2 (ja) 核酸を含有する組成物、その製造および使用
US6020202A (en) Composition and methods for transfecting eukaryotic cells
ES2278556T3 (es) Virus adeno asociado recombinante.
Harada et al. Highly efficient suicide gene expression in hepatocellular carcinoma cells by Epstein-Barr virus-based plasmid vectors combined with polyamidoamine dendrimer
SK111897A3 (en) Pharmaceutical composition suitable for nucleic acid transfection and use such composition for transferring nucleic acid
RO117861B1 (ro) Complex de acid nucleic si compozitie pentru introducerea acestuia in celulele eucariote superioare
US5962429A (en) Complexes of adenovirus with cationic molecules
US7919310B2 (en) Constitutive gene expression in conjunction with ionizing radiation
SK40098A3 (en) Pharmaceutical composition useful for nucleic acid transfection, and use thereof
SK70999A3 (en) Transfecting composition usable in gene therapy combining a recombinant virus incorporating an exogenous nucleic acid, a non-viral and non-plasmid transfecting agent
SK108299A3 (en) Formulation of stabilised cationic transfection agent(s)/nucleic acid particles
EP1108048A1 (fr) Complexes cationiques d'adenovirus modifie par polymere
Suzuki et al. Gene Therapy for Lung Diseases Development in the Vector Biology and Novel Concepts for Gene Therapy Applications
EP1363676B1 (fr) Procede pour renforcer l'efficacite de l'apport d'un acide nucleique therapeutique
AU2002237910A1 (en) Method of enhancing delivery of a therapeutic nucleic acid
KR100241685B1 (ko) 핵산 복합체를 고등 진핵세포내로 도입시키기 위한 조성물
EP1829555A2 (fr) Procédé d'amélioration de distribution d'acide nucléique thérapeutique
MXPA97006016A (en) Composition containing nucleic acids, preparation and use
MXPA98001920A (en) Pharmaceutical composition useful for the transfection of nucleic acids and its u